BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27320877)

  • 1. [Entecavir combined with Fufang Biejia Ruangan tablet in treatment of chronic hepatitis B patients with liver fibrosis: 96-week efficacy analyses].
    Yang NH; Yuan GS; Zhou YC; Liu JW; Huang HP; Hu CG; Xiong L; Li Y; Zhou FY; Yang SL; Zhou YP
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Jun; 36(6):775-9. PubMed ID: 27320877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical effect of combination therapy with Fufang Biejia Ruangan tablet and entecavir in patients with hepatitis B virus-related cirrhosis].
    Wu G; He H; Li H; Chen W
    Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):604-8. PubMed ID: 25243962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety of Fufang Biejia Ruangan tablet in patients with chronic hepatitis B complicated with hepatic fibrosis].
    Chen JM; Yang YP; Chen DY; Han J; Jin XY; Huang ZX; Xu CB; Shen YM
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Dec; 21(4):358-60. PubMed ID: 18322602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of Fufang Biejia Ruangan Tablets as an adjuvant treatment for chronic hepatitis B liver fibrosis: A systematic review and meta-analysis.
    Meng X; Pan Z; Zhao J; Feng Q
    Medicine (Baltimore); 2022 Nov; 101(46):e31664. PubMed ID: 36401442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy Observation of Yiguanjian Decoction Combined Adefovir Dipivoxil Tablet in Treating HBeAg Negative Chronic Viral Hepatitis B Active Compensated Liver Cirrhosis Patients].
    Duan SH; Bao ZY; Yuan XD; Wang L; Liu MS
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 May; 36(5):535-8. PubMed ID: 27386642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Fufang Biejia Ruangan Tablet on lowering biochemical and virological parameters of hepatic fibrosis in patients with chronic hepatitis B: Protocol for a systematic review and meta-analysis of randomized controlled trials and cohort studies.
    Huang C; Shen D; Sun S; Huang Y; Xin Y; Luo H; Chen Y; Zhou Z; Liu F; Chen X
    Medicine (Baltimore); 2019 Apr; 98(17):e15297. PubMed ID: 31027094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study on rational daily administration frequency of Fufang Biejia Ruangan tablet based on integrated serum pharmacologic and pharmacokinetic model].
    Bai JX; Dai L; Chen HG; Xu H; Yin RL; Han J; Yuan HL
    Zhongguo Zhong Yao Za Zhi; 2013 Jul; 38(14):2394-8. PubMed ID: 24199579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD; Chen XF; Zhou Y; Chen XP
    J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Fuzheng Huayu tablet on antiviral effect of entecavir in patients with hepatitis B cirrhosis.
    Cheng DY; Zhao ZM; Wan G; Zheng HW; Huang JQ; Liu CH; Xing HC
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):479-484. PubMed ID: 35346577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
    Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.
    Tsai MC; Lee CM; Chiu KW; Hung CH; Tung WC; Chen CH; Tseng PL; Chang KC; Wang JH; Lu SN; Yen YH; Hu TH
    J Antimicrob Chemother; 2012 Mar; 67(3):696-9. PubMed ID: 22174039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compound Biejia-Ruangan tablet as an adjunctive therapy to entecavir for chronic hepatitis B complicated with hepatic fibrosis: A systematic review and meta-analysis of randomized controlled trials.
    Xu YH; Xue C
    Medicine (Baltimore); 2022 Aug; 101(32):e30020. PubMed ID: 35960113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial.
    Qu J; Yu Z; Li Q; Chen Y; Xiang D; Tan L; Lei C; Bai W; Li H; Shang Q; Chen L; Hu X; Lu W; Li Z; Chen D; Wang X; Zhang C; Xiao G; Qi X; Chen J; Zhou L; Chen G; Li Y; Zeng Z; Rong G; Dong Z; Chen Y; Lou M; Wang C; Lu Y; Zhang C; Yang Y
    Trials; 2014 Nov; 15():438. PubMed ID: 25381721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients.
    Jeng WJ; Sheen IS; Chen YC; Hsu CW; Chien RN; Chu CM; Liaw YF
    Hepatology; 2013 Dec; 58(6):1888-96. PubMed ID: 23744454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
    Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
    Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
    Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
    Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.
    Wu IC; Lai CL; Han SH; Han KH; Gordon SC; Chao YC; Tan CK; Sievert W; Tanwandee T; Xu D; Neo BL; Chang TT
    Hepatology; 2010 Apr; 51(4):1185-9. PubMed ID: 20044806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.